PMID- 30190925
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2045-0893 (Electronic)
IS  - 2045-0885 (Print)
IS  - 2045-0885 (Linking)
VI  - 4
IP  - 4
DP  - 2017 Dec
TI  - Management of the cutaneous adverse effects of antimelanoma therapy.
PG  - 187-202
LID - 10.2217/mmt-2017-0015 [doi]
AB  - The advent of targeted therapy and immunotherapy has revolutionized the 
      management of advanced melanoma. However, these novel therapies are associated 
      with adverse effects (AEs), of which cutaneous toxicities are the most frequently 
      observed. These cutaneous AEs can exert significant morbidity and impact on 
      patient quality of life, hence the recognition and management of AEs is 
      fundamental in preventing interruption or cessation of survival-prolonging 
      treatments. Additionally, knowledge of these AEs are necessary in order for 
      healthcare professionals to counsel patients when starting treatment and in the 
      initiation of AE prophylaxis. The incidence and clinical presentation of the 
      cutaneous toxicities of novel melanoma therapies will be discussed, and treatment 
      guidelines provided.
FAU - Liu, Rose Congwei
AU  - Liu RC
AD  - Department of Dermatology, Westmead Hospital, Sydney 2145, Australia.
AD  - Westmead Clinical School, University of Sydney Medical School, Sydney 2145, 
      Australia.
AD  - Department of Dermatology, Westmead Hospital, Sydney 2145, Australia.
AD  - Westmead Clinical School, University of Sydney Medical School, Sydney 2145, 
      Australia.
FAU - Consuegra, Germana
AU  - Consuegra G
AD  - Department of Dermatology, Westmead Hospital, Sydney 2145, Australia.
AD  - Westmead Clinical School, University of Sydney Medical School, Sydney 2145, 
      Australia.
AD  - Department of Dermatology, Westmead Hospital, Sydney 2145, Australia.
AD  - Westmead Clinical School, University of Sydney Medical School, Sydney 2145, 
      Australia.
FAU - Fernandez-Penas, Pablo
AU  - Fernandez-Penas P
AD  - Department of Dermatology, Westmead Hospital, Sydney 2145, Australia.
AD  - Westmead Clinical School, University of Sydney Medical School, Sydney 2145, 
      Australia.
AD  - Department of Dermatology, Westmead Hospital, Sydney 2145, Australia.
AD  - Westmead Clinical School, University of Sydney Medical School, Sydney 2145, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171122
PL  - England
TA  - Melanoma Manag
JT  - Melanoma management
JID - 101649842
PMC - PMC6094689
OTO - NOTNLM
OT  - B-raf inhibitors
OT  - adverse drug reactions
OT  - anti-CTLA-4
OT  - anti-PD-1
OT  - cutaneous adverse event
OT  - metastatic melanoma
OT  - mitogen-activated protein kinase inhibitor
OT  - skin (melanoma)
OT  - targeted therapy
COIS- Financial & competing interests disclosure The authors have no relevant 
      affiliations or financial involvement with any organization or entity with a 
      financial interest in or financial conflict with the subject matter or materials 
      discussed in the manuscript. This includes employment, consultancies, honoraria, 
      stock ownership or options, expert testimony, grants or patents received or 
      pending, or royalties. No writing assistance was utilized in the production of 
      this manuscript.
EDAT- 2018/09/08 06:00
MHDA- 2018/09/08 06:01
PMCR- 2017/12/01
CRDT- 2018/09/08 06:00
PHST- 2017/06/04 00:00 [received]
PHST- 2017/10/17 00:00 [accepted]
PHST- 2018/09/08 06:00 [entrez]
PHST- 2018/09/08 06:00 [pubmed]
PHST- 2018/09/08 06:01 [medline]
PHST- 2017/12/01 00:00 [pmc-release]
AID - 10.2217/mmt-2017-0015 [doi]
PST - ppublish
SO  - Melanoma Manag. 2017 Dec;4(4):187-202. doi: 10.2217/mmt-2017-0015. Epub 2017 Nov 
      22.